| DESCRIPTION | - DALL'ERA, M et al., Arth. Care and Res, (20110000), vol. 63, pages 351 - 357 | - |
| INTERNATIONAL-SEARCH-REPORT | - AURINIA PHARMACEUTICALS, "Aurinia highlights 48-week data from open-label AURION study at 12th International Congress on SLE (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017", Press Release, (20170327), URL: https://ir.auriniapharma.com/press-releases/detail/81, (20181119), XP055677565 [X] 17-21 *the whole document* | - |
| INTERNATIONAL-SEARCH-REPORT | - AURINIA PHARMACEUTICALS, "Aurinia releases additional 48-week data from the AURA-LV Study during late-breaking session at the National Kidney Foundation 2017 Spring Clinical Meetings", Press Release, (20170420), URL: https://ir.auriniapharma.com/press-releases/detail/85/aurinia-releases-additional-48-week-data-from-the-aura-lv, (20161119), XP055677560 [Y] 17-21 *the whole document* | - |
| INTERNATIONAL-SEARCH-REPORT | - PENDERGRAFT, W.F., "AURA-LV: Successful treatment of active lupus nephritis with voclosporin", Journal of the American Society of Nephrology, (20161100), vol. 27, page 2B, XP055677563 [Y] 17-21 * , Abstract No. HI-OR05, ISSN 1533-3450 (electronic) & PENDERGRAFT, W.F. AURA-LV: Successful treatment of active lupus nephritis with voclosporin. Kidney Week 2016, 15-20 November 2016 [Slideshow of Oral Communication presented by W.F. Pendergraft at the High Impact Clinical Trials Session] [online], [retrieved on 19 November 2018]. Retrieved from <http://c.eqcdn.com/ 01827f689f60c2019181b298b7efla8e/auriniapharma/db/246/851/p df/2016-11-19+ASN hieh+impact+clinical+trials+session+reduced.pdf> *the whole document* | - |
| INTERNATIONAL-SEARCH-REPORT | - YAHYA, R. et al., "AURION Study: 12 week data of multi-target therapy with voclosporin, MMF and steroids for lupus nephritis", Clinical and Experimental Rheumatology, (20161005), vol. 34, no. Issue Number 4, Suppl. 99, page S-15, XP009519458 [X] 1, 2, 7-12, 14, 22 * [Abstract for oral communication]. In: Clinical and Experimental Rheumatology, Vol. 34(4), Suppl. 99, 2016, Abstract S8:06, ISSN 1593-098X (electronic) & YAHYA, R. et al. AURION Study: 12 week data of multi-target therapy with voclosporin, MMF and steroids for lupus nephritis. 10th European Lupus Meeting, 5-8 October 2016 [Slideshow of Oral Communication presented by R.B. Huizinga on 6 October 2016] [online], [retrieved on 19 November 2018]. Retrieved from <http://c.eqcdn.com/ 637f156602030d2a0b76a9eeb6b7a54a/auriniapharma/db/246/731/pdf/201 5-10-06+European+Lupus+Meeting+ 2016.pdf> *the whole document* [Y] 3-6, 13, 15-21 | - |
| INTERNATIONAL-SEARCH-REPORT | - HUIZINGA, R.B. et al., "AURION Study: 48-week data of multi-target therapy with voclosporin, MMF and steroids for lupus nephritis", The 12th International Congress on Systemic Lupus Erythematosus (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017, (20170327), URL: http://c.eqcdn.com/349da054eda96a4b6781a0902e2929ab/auriniapharma/db/246/910/pdf/LUPUS+2017+PresentationFINAL.pdf, (20181119), XP055677571 [X] 17-21 *the whole document* | |
| OPPOSITION | - 10th European Lupus Meeting, Final Program, Venice 2016 | - |
| OPPOSITION | - Anonymous, "A brief history on the estimation of Glomerular Filtration Rate", (20210204), pages 1 - 7, URL: https://www.gentian.com/news/cystatin-c-glomerular-filtration-rate, XP093195288 | - |
| OPPOSITION | - Anonymous, "AFINITOR (everolimus) tablets for oral administration ", HIGHLIGHTS OF PRESCRIBING INFORMATION, (20120701), pages 1 - 36, XP093195312 | - |
| OPPOSITION | - Anonymous, "AURA-LV: Aurinia Urinary Protein Reduction Active -Lupus With Voclosporin (AURA-LV) (AURA-LV)", ClinicalTrials.gov NCT02141672, (20170322), ClinicalTrials.gov NCT02141672, URL: https://clinicaltrials.gov/study/NCT02141672?term=AURA-LV&tab=history&a=14#version-content-panel, XP093195658 | - |
| OPPOSITION | - Anonymous, "AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)", ClinicalTrials.gov - History of Changes for Study: NCT02141672, (20160426), ClinicalTrials.gov - History of Changes for Study: NCT02141672, URL: https://clinicaltrials.gov/study/NCT02141672?tab=history&a=16#version-content-panel, XP093194327 | - |
| OPPOSITION | - Anonymous, "AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)", History of Changes for Study: NCT02141672, (20150630), History of Changes for Study: NCT02141672, URL: https://clinicaltrials.gov/ct2/history/NCT02141672?A=10&B=10&C=merged#StudyPageTop , XP093194947 | - |
| OPPOSITION | - Anonymous, "Aurinia Announces Acceptance of Late-Breaking Voclosporin Abstracts for Oral Presentation at Upcoming Medical Meetings", (20161024), URL: http://www.businesswire.com/news/home/20161024006470/en/, XP093195324 | - |
| OPPOSITION | - Anonymous, "Aurinia Announces Voclosporin Meets 48-Week Remission Endpoints, Achieving Highest Complete Remission Rate of Any Global Lupus Nephritis Study", (20170301), URL: http://www.businesswire.com/news/home/20170301006343/en/, XP093195308 | - |
| OPPOSITION | - Anonymous, "Aurinia Announces Voclosporin Meets 48-Week Remission Endpoints, Achieving Highest Complete Remission Rate of Any Global Lupus Nephritis Study", Aurinia Pharmaceuticals Inc. - Press Release, (20170301), Aurinia Pharmaceuticals Inc. - Press Release , URL: https://d1io3yog0oux5.cloudfront.net/_f90b15eac698097d9bf8b5a9e1f8b758/auriniapharma/news/2017-03-01_Aurinia_Announces_Voclosporin_Meets_48_Week_73.pdf, XP093195664 | - |
| OPPOSITION | - Anonymous, "Aurinia Early Urinary Protein Reduction Predicts Response (AURION)", ClinicalTrials.gov NCT02949973, (20170321), ClinicalTrials.gov NCT02949973, URL: https://clinicaltrials.gov/study/NCT02949973?tab=history&a=5#version-content-panel, XP093195673 | - |
| OPPOSITION | - Anonymous, "Aurinia Early Urinary Protein Reduction Predicts Response (AURION)", ClinicalTrials.gov NCT02949973, (20170920), ClinicalTrials.gov NCT02949973, URL: https://clinicaltrials.gov/study/NCT02949973?tab=history&a=4#version-content-panel, XP093195670 | - |
| OPPOSITION | - Anonymous, "Aurinia Highlights 48-Week Data from Open-Label AURION Study at 12th International Congress on SLE (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017)", Aurinia Pharmaceuticals Inc. - Press Release, (20170327), Aurinia Pharmaceuticals Inc. - Press Release, URL: https://d1io3yog0oux5.cloudfront.net/_f90b15eac698097d9bf8b5a9e1f8b758/auriniapharma/news/2017-03-27_Aurinia_Highlights_48_Week_Data_from_Open_Label_81.pdf, XP093195667 | - |
| OPPOSITION | - Anonymous, "Aurinia Highlights Renal Function Data from Global Phase IIb AURA Study of Voclosporin for Lupus Nephritis at American Society of Nephrology Kidney Week 2016", Business Wire News Release, (20161121), XP093195327 | - |
| OPPOSITION | - Anonymous, "Aurinia Releases Open-Label AURION Data Demonstrating Increased Remission Rates over Time for Voclosporin in the Treatment of Lupus Nephritis", Aurinia Pharmaceuticals Inc. - Press Release, (20161006), Aurinia Pharmaceuticals Inc. - Press Release, URL: https://d1io3yog0oux5.cloudfront.net/_f90b15eac698097d9bf8b5a9e1f8b758/auriniapharma/news/2016-10-06_Aurinia_Releases_Open_Label_AURION_Data_54.pdf, XP093195668 | - |
| OPPOSITION | - Anonymous, "Aurinia Reports First Quarter 2017 Financial Results, Announces Initiation of Phase III Aurora Clinical Trial, and Provides Operational Highlights", Aurinia Pharmaceuticals Inc - Press Releases, (20170515), Aurinia Pharmaceuticals Inc - Press Releases, URL: https://d1io3yog0oux5.cloudfront.net/_f90b15eac698097d9bf8b5a9e1f8b758/auriniapharma/news/2017-05-15_Aurinia_Reports_First_Quarter_2017_Financial_88.pdf, XP093195662 | - |
| OPPOSITION | - Anonymous, "Isotechnika Merger With Aurinia to Create Leading Nephrology Company", Press Release Globe Newswire, (20130205), XP093195317 | - |
| OPPOSITION | - Anonymous, "JARDIANCE® (empagliflozin) tablets, for oral use", HIGHLIGHTS OF PRESCRIBING INFORMATION, (20140801), pages 1 - 28, XP093195332 | - |
| OPPOSITION | - Anonymous, "#KidneyWk 2016: High Impact Clinical Trials", AJKDblog, (20161120), AJKDblog, XP093195331 | - |
| OPPOSITION | - Anonymous, "What is lupus nephritis?", (20210123), pages 1 - 2, URL: https://www.lupus.org/resources/what-is-lupus-nephritis, XP093195279 | - |
| OPPOSITION | - Aurinia, "Aurinia Highlights 48-Week Data from Open-Label AURION Study at 12th International Congress on SLE (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017)", (20170327), URL: https://d1io3yog0oux5.cloudfront.net/_9b66504bd697f607c9b0a249b4c983da/auriniapharma/news/2017-03-27_Aurinia_Highlights_48_Week_Data_from_Open_Label_81.pdf, (20200318), XP055677565 | - |
| OPPOSITION | - Aurinia, "Aurinia Releases Additional 48-Week Data from the AURA-LV Study During Late- Breaking Session at the National Kidney Foundation 2017 Spring Clinical Meetings", (20170420), URL: https://d1io3yog0oux5.cloudfront.net/_9b66504bd697f607c9b0a249b4c983da/auriniapharma/news/2017-04-20_Aurinia_Releases_Additional_48_Week_Data_from_the__85.pdf, (20200318), XP055677560 | - |
| OPPOSITION | - "Chapters 2, 3, 4, 10, 26, 71, 77, 79, 80, 81, 101", Johnson Richard J., Feehally John, Floege Jurgen, Comprehensive Clinical Nephrology, 5th ed., (20150101), pages 14 - 52, 184 - 197, 303 - 316, 827 - 835, 884 - 904, 916 - 948, 1144 - 1151, XP093194959 | - |
| OPPOSITION | - CLINICAL PRACTICE GUIDELINES, (2002), page 356pp | - |
| OPPOSITION | - Dooley Mary Anne, Pendergraft William, Ginzler Ellen M, Olsen Nancy, Tumlin James, Rovin6 Brad H, Houssiau Frederic A, Wofsy David, Isenberg David A, Solomons Neil, "Speed of Remission with the Use of Voclosporin, MMF and Low Dose Steroids: Results of a Global Lupus Nephritis Study", 2016 ACR/ARHP Annual Meeting, (20161019), XP093195663 | - |
| OPPOSITION | - Ema, "Lupkynis", ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, (20220915), ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, URL: https://ec.europa.eu/health/documents/community-register/2022/20220915156788/anx_156788_en.pdf, XP093195698 | - |
| OPPOSITION | - Fda, "LUPKYNIS (voclosporin) capsules, for oral use ", HIGHLIGHTS OF PRESCRIBING INFORMATION, (20210101), HIGHLIGHTS OF PRESCRIBING INFORMATION, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213716s000lbl.pdf, XP093195692 | - |
| OPPOSITION | - Gov Clinicaltrials, Pharmaceuticals Aurinia, "AURA-LV: Aurinia Urinary Protein Reduction Active -Lupus With Voclosporin (AURA-LV) (AURA-LV)", ClinicalTrials.gov NCT02141672, (20170925), ClinicalTrials.gov NCT02141672, URL: https://clinicaltrials.gov/study/NCT02141672?tab=history, XP093195657 | - |
| OPPOSITION | - Hiroe Ogawa ; Hideto Kameda ; Hayato Nagasawa ; Naoya Sekiguchi ; Hirofumi Takei ; Kensei Tsuzaka ; Koichi Amano ; Tsutomu Takeuchi, "Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis", Modern Rheumatology ; Official Journal of the Japan College of Rheumatology, Springer-Verlag, To, To , (20070420), vol. 17, no. 2, ISSN 1439-7609, pages 92 - 97, XP019495261 | - |
| OPPOSITION | - Huizinga R. B., R. Yahya, A.H.A. Gafor, N. Solomons, L. Veasey, "AURION Study: 48-week data of multi-target therapy with voclosporin, MMF and steroids for lupus nephritis", The 12th International Congress on Systemic Lupus Erythematosus (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017), (20170327), pages 1 - 24, The 12th International Congress on Systemic Lupus Erythematosus (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017), URL: https://d1io3yog0oux5.cloudfront.net/_204eb7ac303225fe441a0f29bdc187fd/auriniapharma/db/246/910/pdf/LUPUS+2017+Presentation_FINAL.pdf, XP093195155 | - |
| OPPOSITION | - Inker Lesley A., Fan Li, Levey Andrew S., Johnson Richard, Floege Jürgen, Tonelli Marcello, "chapter 3, 77, 79, 81", Comprehensive clinical nephrology. 5th Ed., Elsevier, (20150101), ISBN 978-1-4557-5838-8, XP093195724 | - |
| OPPOSITION | - Katzung Bertram G., Masters Susan B, Trevor Anthony J, Basic & Clinical Pharmacology, 12th ed., (20120101), pages 13 - 68, XP093195645 | - |
| OPPOSITION | - Kegel Magdalena, "Lupus Nephritis Therapy in Phase 2b Study", Lupus News Today, (20161129), XP093195322 | - |
| OPPOSITION | - Levey Andrew S, Bosch Juan P, Lewis Julia Breyer, Greene Tom, Rogers Nancy, Roth David, "A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation", Annals of Internal Medicine, (19990101), vol. 130, pages 461 - 470, XP093195280 | - |
| OPPOSITION | - Mcclellan William M, Schoolwerth Anton C, Gehr Todd, "1. Chronic Kidney Disease (CKD): Definition. 2 Detection of CKD: Estimation of Glomerular Filtration Rate", Clinical Management of Chronic Kidney Disease. 1st Ed., Professional Communications, Inc., (20060101), pages 13 - 36, ISBN 978-1-932610-04-8, XP093195707 | - |
| OPPOSITION | - National Institute For Health And Care Excellence, "4-year surveillance (2017) - Chronic kidney disease in adults", NICE guideline CG182, (20140101), pages 1 - 48, XP093194944 | - |
| OPPOSITION | - Naughton Cynthia A., "Drug-Induced Nephrotoxicity", American Family Physician - AFP, American Academy of Family Physicians, (20080915), vol. 78, no. 6, pages 743 - 750, XP093195676 | - |
| OPPOSITION | - Naughton Cynthia A., "Drug-Induced Nephrotoxicity", AMERICAN FAMILY PHYSICIAN, American Academy of Family Physicians, US, US , (20080101), vol. 78, no. 6, ISSN 0002-838X, pages 743 - 750, XP093194939 | - |
| OPPOSITION | - Nice, "Chronic kidney disease in adults: assessment and management", NIICE. National Institute for Health and Care Excellence - Clinical guideline, (20140723), NIICE. National Institute for Health and Care Excellence - Clinical guideline, URL: https://www.nice.org.uk/, XP093195679 | - |
| OPPOSITION | - Nkf, "For Chronic Kidney Disease: Evaluation, Classification and Stratification", NKF. National Kidney Foundation - CLINICAL PRACTICE GUIDELINES, (20020101), pages 1 - 356, NKF. National Kidney Foundation - CLINICAL PRACTICE GUIDELINES, XP093195722 | - |
| OPPOSITION | - Papp Kim, Bissonnette R, Rosoph L, Wasel N, Lynde C W, Searles G, Maksymowych W P, "Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study", Lancet, (20080419), vol. 371, pages 1337 - 1342, XP093194951 | - |
| OPPOSITION | - Rayner Hugh C., Thomas Mark, Milford David, "Chapter 1. Chapter 8 ", Understanding Kidney Diseases, Springer International Publishing, (20160101), pages 1 - 29, 103- 115, XP093195686 | - |
| OPPOSITION | - R.B. Huizinga, R. Yahya, A.H.A. Gafor, N. Solomons, L. Veasey, "AURION Study: 48-week data of multi-target therapy with voclosporin, MMF and steroids for lupus nephritis", The 12th International Congress on Systemic Lupus Erythematosus (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017, (20170326), pages 1 - 24, XP009548069 | - |
| OPPOSITION | - Wilding John, Kirby Mike, Evans Marc, "Prescribing antidiabetic drugs for patients with renal dysfunction", Prescriber, (20111005), pages 65 - 70, XP093194945 | - |
| OPPOSITION | - William F Pendergrai, Tumlin James A, Rovin Brad H, Dooley Mary Anne, Jayne David R W, Wofsy David, Houssiau Frederic A, Isenberg David, Mao Tak, Chan, Solomons Neil, Huizinga Robert B, "AURA-LV: successful treatment of ac5ve lupus nephri5s with voclosporin 111916 High Impact Clinical Trials Session", (20161101), URL: http://c.eqcdn.com/_01827f689f60c2019181b298b7ef1a8e/auriniapharma/db/246/851/pdf/2016-11-19+ASN_high+impact+clinical+trials+session+reduced.pdf, (20200318), XP055677563 | - |
| OPPOSITION | - Yahya, R.; Abdul Gafor, A.H.; Chan, T.M.; Huizinga, R.; Solomons, N., "AURION Study: 12 week data of multi-target therapy with voclosporin, MMF and steroids for lupus nephritis", CLINICAL AND EXPERIMENTAL RHEUMATOLOGY., PACINI, PISA, IT, IT , (20161005), vol. 34, no. 4, Suppl. 99, ISSN 0392-856X, page S15, XP009519458 | - |
| OPPOSITION | - Yahya, R.; Abdul Gafor, A.H.; Chan, T.M.; Huizinga, R.; Solomons, N., "AURION Study: 12 week data of multi-target therapy with voclosporin, MMF and steroids for lupus nephritis", CLINICAL AND EXPERIMENTAL RHEUMATOLOGY., PACINI, PISA, IT, IT , (20161005), vol. 34, no. 4, Suppl. 99, ISSN 0392-856X, pages S - 15, XP009519458 | - |
| OPPOSITION | - Yahya R., A.H. Abdul Gafor, T.M.Chan, R. Huizinga1, N. Solomons, "S8:06 Aurion Study: 12 Week Data of Multi-Target Therapy With Voclosporin, MMF And Steroids For Lupus Nephritis", 10th European Lupus Meeting. Oral Communications, (20160101), pages S - 15, 10th European Lupus Meeting. Oral Communications, XP093194332 | - |
| OPPOSITION | - Yahya R., A.H. Abdul Gafor, T.M.Chan, R. Huizinga, N. Solomons, "S8:06. AURION STUDY: 12 WEEK DATA OF MULTI-TARGET THERAPY WITH VOCLOSPORIN, MMF AND STEROIDS FOR LUPUS NE PHRITIS", 10th European Lupus Meeting. Clinical and Experimental RHEUMATOLOGY, Venice, Italy, Venice, Italy, (20161001), vol. 34, page S15, XP093195666 | - |
| OPPOSITION | - Ling S.Y., Huizinga R.B., Mayo P.R., Freitag D.G., Aspeslet L.J., Foster R.T., "Pharmacokinetics of voclosporin in renal impairment and hepatic impairment : The Journal of Clinical Pharmacology", The Journal of clinical pharmacology, LIPPINCOTT CO, HAGERSTOWN, MD, US, US , (20131201), vol. 53, no. 12, doi:10.1002/jcph.166, ISSN 0091-2700, pages 1303 - 1312, XP093194965 | |
| OPPOSITION | - Wilding John, Kirby Mike, Evans Marc, "Prescribing antidiabetic drugs for patients with renal dysfunction", Prescriber, John Wiley & Sons, Inc., Hoboken, USA, Hoboken, USA, (20111005), vol. 22, no. 19, doi:10.1002/psb.815, ISSN 0959-6682, pages 65 - 70, XP093195681 | |
| OPPOSITION | - Bissonnette, R. Papp, K. Poulin, Y. Lauzon, G. Aspeslet, L. Huizinga, R. Mayo, P. Foster, R.T. Yatscoff, R.W. Maksymowych, W.P., "A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis", Journal of the American Academy of Dermatology, Mosby, Inc, US, US , (20060301), vol. 54, no. 3, doi:10.1016/j.jaad.2005.10.061, ISSN 0190-9622, pages 472 - 478, XP005292125 | |
| OPPOSITION | - Kim Papp, Richard Langley, Robert Bissonnette, Les Rosoph, "A Phase III, randomized, multicenter, double-blind, placebo-controlled study of ISA247 in plaque psoriasis patients", Journal of the American Academy of Dermatology, Mosby, Inc, US, US , (20060301), vol. 54, no. 3, doi:10.1016/j.jaad.2005.11.036, ISSN 0190-9622, pages AB8 - AB10, XP005416774 | |
| OPPOSITION | - Rovin Brad H., Rovin Brad H., Solomons Neil, Pendergraft William F., Dooley Mary Anne, Tumlin James, Romero-Diaz Juanita, Lysenko Lidia, Navarra Sandra V., Huizinga Robert B., Adzerikho Ihar, Mikhailova Elena, Mitkovskaya Natalya, Pimanov Sergey, Soroka Nikolay, Bogov Boris Iliev, Deliyska Boriana, Ikonomov Valentin, Tilkiyan Eduard, Almeida Ruth, Jimenez Fernando, Teran Faud, Tchokhonelidze Irma, Tsiskarishvili Nino, Herrera Mendez Maynor, Loaeza Arturo Reyes, Gutierrez Urena Sergio Ramon Et Al., "A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis", Kidney International, Elsevier, United States, United States, (20190101), vol. 95, no. 1, doi:10.1016/j.kint.2018.08.025, ISSN 0085-2538, pages 219 - 231, XP093195272 | |
| OPPOSITION | - Daughton Christian G., Ruhoy Ilene Sue, "Lower-dose prescribing: Minimizing “side effects” of pharmaceuticals on society and the environment", Science of The Total Environment, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20121129), vol. 443, doi:10.1016/j.scitotenv.2012.10.092, ISSN 0048-9697, pages 324 - 337, XP055939297 | |
| OPPOSITION | - Papp, K. ; Bissonnette, R. ; Rosoph, L. ; Wasel, N. ; Lynde, C. ; Searles, G. ; Shear, N. ; Huizinga, R. ; Maksymowych, W., "Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20080419), vol. 371, no. 9621, doi:10.1016/S0140-6736(08)60593-0, ISSN 0140-6736, pages 1337 - 1342, XP022615774 | |
| OPPOSITION | - Keane William F.; Eknoyan Garabed, "Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation", American Journal of Kidney Diseases, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (1999), vol. 33, no. 5, doi:10.1016/S0272-6386(99)70442-7, ISSN 0272-6386, pages 1004 - 1010, XP028840974 | |
| OPPOSITION | - Chang David Ray, Yeh Hc, Ting Iw, Lin Cy, Huang Hc, Chiang Hy, Chang Sn, Tsai Hc, Lo Yc, Hsiao Ct, Chu Pl, Kuo Cc. , "The ratio and difference of urine protein-to-creatinine ratio and albumin-to-creatinine ratio facilitate risk prediction of all-cause mortality", Scientific Reports, (20210412), vol. 11, no. 1, doi:10.1038/s41598-021-86541-3, page 7851, XP093195286 | |
| OPPOSITION | - Li X., Ren H., Zhang Q., Zhang W., Wu X., Xu Y., Shen P., Chen N., "Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis", Nephrology Dialysis Transplantation, Oxford university Press, GB, GB , (20120401), vol. 27, no. 4, doi:10.1093/ndt/gfr484, ISSN 0931-0509, pages 1467 - 1472, XP093195296 | |
| OPPOSITION | - Solomons Neil, Abdul Gafor Abdul Halim, Yahya Rosnawati, Chan Tak Mao, Huizinga Robert, "MP130AURION STUDY: MULTI-TARGET THERAPY WITH VOCLOSPORIN, MMF AND STEROIDS FOR LUPUS NEPHRITIS", Nephrology Dialysis Transplantation, Oxford university Press, GB, GB , (20160501), vol. 31, no. suppl_1, doi:10.1093/ndt/gfw185.21, ISSN 0931-0509, pages i385 - i385, XP093195157 | |
| OPPOSITION | - Boele-Schutte Elise, Gansevoort Ron T., "Measured GFR: not a gold, but a gold-plated standard", Nephrology Dialysis Transplantation, Oxford university Press, GB, GB , (20170401), vol. 32, no. suppl_2, doi:10.1093/ndt/gfw441, ISSN 0931-0509, pages ii180 - ii184, XP093195283 | |
| OPPOSITION | - Powles A.V., Carmichael D., Hulme B., Thomas E., Mcfadden J., Baker B., Valdimarsson H., Fry L., "Renal function after long-term low-dose cyclosporin for psoriasis", British journal of dermatology (1951), Wiley, (19900501), vol. 122, no. 5, doi:10.1111/j.1365-2133.1990.tb07288.x, ISSN 0007-0963, pages 665 - 669, XP093194935 | |
| OPPOSITION | - Mok Chi Chiu, Tong Ka Hang, To Chi Hung, Siu Yui Pong, Au Tak Cheung, "Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: An open-labeled pilot study", Kidney International, Elsevier, United States, United States, (20050801), vol. 68, no. 2, doi:10.1111/j.1523-1755.2005.00461.x, ISSN 0085-2538, pages 813 - 817, XP093194333 | |
| OPPOSITION | - S. Busque; M. Cantarovich; S. Mulgaonkar; R. Gaston; A. O. Gaber; P. R. Mayo; S. Ling; R. B. Huizinga; H‐U. Meier‐Kriesche, "The PROMISE Study: A Phase 2b Multicenter Study of Voclosporin (ISA247) Versus Tacrolimus in De Novo Kidney Transplantation", American journal of transplantation, BLACKWELL MUNKSGAARD, DK, DK , (20110922), vol. 11, no. 12, doi:10.1111/j.1600-6143.2011.03763.x, ISSN 1600-6135, pages 2675 - 2684, XP072349825 | |
| OPPOSITION | - Rb Huizinga, R Yahya, Aha Gafor, N Solomons, L Veasey, "20 Aurion study: 24-week data of multi-target therapy with voclosporin, mmf and steroids for active lupus nephritis", Lupus Science & Medicine, Lupus Foundation of America, BMJ, BMJ , (20170301), vol. 4, no. Suppl. 1, doi:10.1136/lupus-2017-000215.20, ISSN 2053-8790, pages A10 - A11, XP055677571 | |
| OPPOSITION | - Rb Huizinga, R Yahya, Aha Gafor, N Solomons, L Veasey, "20: Aurion study: 24-week data of multi-target therapy with voclosporin, mmf and steroids for active lupus nephritis", Lupus Science & Medicine, Lupus Foundation of America, BMJ, BMJ , (20170301), vol. 4, no. Suppl. 1, doi:10.1136/lupus-2017-000215.20, ISSN 2053-8790, pages A10 - A11, XP055677571 | |
| OPPOSITION | - Ogawa H., Kameda H., Amano K., Takeuchi T., "Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice", LUPUS, Sage, GB, GB , (20100201), vol. 19, no. 2, doi:10.1177/0961203309350320, ISSN 0961-2033, pages 162 - 169, XP093194324 | |
| OPPOSITION | - Zavada J., Pešickova Ss, Ryšava R., Olejarova M., Horák P., Hrnčíř Z., Rychlík I., Havrda M., Vítova J., Lukáč J., Rovensky J., Tegzova D., Böhmova J., Zadražil J., Hána J., Dostál C., Tesar V., "Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study", LUPUS, Sage, GB, GB , (20101001), vol. 19, no. 11, doi:10.1177/0961203310371155, ISSN 0961-2033, pages 1281 - 1289, XP093195153 | |
| OPPOSITION | - Sung Hae Ha;Ji Hyeon Park;Hye Ryoun Jang;Wooseong Huh;Ho-Yeong Lim;Yoon-Goo Kim;Dae Joong Kim;Ha Young Oh;Jung Eun Lee, "Increased risk of everolimus-associated acute kidney injury in cancer patients with impaired kidney function", BMC Cancer, BIOMED CENTRAL, LONDON, GB, LONDON, GB , (20141203), vol. 14, no. 1, doi:10.1186/1471-2407-14-906, ISSN 1471-2407, page 906, XP021204734 | |
| OPPOSITION | - Samir V Parik, Brad H Rovin, "Current and Emerging Therapies for Lupus Nephritis", J Am Soc Nephrol., (2016), vol. 27, no. 10, doi:10.1681/ASN.2016040415, pages 2929 - 2939, XP055443218 | |
| OPPOSITION | - Wang Pusen, Que Weitao, Li Hao, Yan Lvnan, Fu Zhiren, Ye Qifa, Chen Guihua, Dou Kefeng, Lu Shichun, Yang Zhanyu, Zhu Zhijun, Peng Zhihai, Zhong Lin, "Efficacy and safety of a reduced calcineurin inhibitor dose combined with mycophenolate mofetil in liver transplant patients with chronic renal dysfunction", Oncotarget, Impact Journals LLC, United States, United States , (20170822), vol. 8, no. 34, doi:10.18632/oncotarget.15490, ISSN 1949-2553, pages 57505 - 57515, XP093194325 | |
| OPPOSITION | - Alamilla-Sanchez Mario E, Alcala-Salgado Miguel A, Alonso-Bello Cesar D, Fonseca-Gonzalez Gandhy T, "Mechanism of Action and Efficacy of Immunosupressors in Lupus Nephritis", International Journal of Nephrology and Renovascular Disease, (20210101), vol. 14, doi:10.2147/IJNRD.S335371, ISSN 1178-7058, pages 441 - 458, XP093195299 | |
| OPPOSITION | - Gheith Osama, Al-Otaibi Toki, Adel Hani, "Next-generation calcineurin inhibitors in development for the prevention of organ rejection", Transplant Research and Risk Management, (20140101), doi:10.2147/TRRM.S35875, ISSN 1179-1616, pages 23 - 30, XP093195270 | |
| OPPOSITION | - Almaani Salem, Meara Alexa, Rovin Brad H., "Update on Lupus Nephritis", Clinical Journal of the American Society of Nephrology, (20170501), vol. 12, no. 5, doi:10.2215/CJN.05780616, ISSN 1555-9041, pages 825 - 835, XP093195293 | |
| OPPOSITION | - Rafael-Vidal Carlos, Altabás Irene, Pérez Nair, Mourino Rodríguez Coral, Pego-Reigosa Jose M., Garcia Samuel, "Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis", International journal of molecular sciences, Molecular Diversity Preservation International (MDPI), Basel, CH, Basel, CH , (20210127), vol. 22, no. 3, doi:10.3390/ijms22031263, ISSN 1422-0067, page 1263, XP093195158 | |
| SEARCH | [ ] - No further relevant documents disclosed | - |
